Faricimab，First time this level of durability has been achieved in Ph III，Filing on track for 2021;
Ph III (YOSEMITE & RHINE) results in DME positive with >50% of patients being able to extend time between treatments to 16 weeks；
Ph III (LUCERNE & TENAYA) results in nAMD positive with nearly half (45%) of patients being treated every 16 weeks；
